Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07572240

A Clinical Trial to Assess the Effect of AP-Brain Collagen Peptides on the Improvement of Attention, Focus, and Memory in Stressed But Otherwise Healthy Individuals

The goal of this clinical trial is to learn about the effects of AP-Brain collagen peptide on attention, focus, and memory in adults who are stressed but otherwise healthy.

The main questions it aims to answer are:

* How does AP-Brain affect a participant's attention, focus, stress, and memory? * Is there a difference in the effects between a higher dose and a lower dose? * What are the side effects, if any, for participants taking AP-Brain?

Researchers will compare two different doses of AP-Brain to see how they affect brain function and stress levels.

Participants in this study will be asked to:

* Take one of two the doses of AP-Brain once a day for 56 days. * Visit the study center for regular checkups. * Complete tasks that measure memory, focus, and attention. * Answer survey questions about their stress levels. * Provide blood samples and have vital signs checked. * Have the brain's response to tasks monitored to see how it affects attention and alertness.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

35 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Omkar ENT Hospital and Research Centre, Nashik, Maharashtra, India

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals ready to give voluntary, written informed consent to participate in the study.
  • Male and female individuals of age between 35 to 70 years (both values included).
  • Individuals with body mass index (BMI) between 18.5 kg/m^2 to 29.9 kg/m^2 (both values included).
  • Perceived Stress Scale (PSS) scores between 14 to 26 (both values included).
  • Individuals with mild cognitive impairment as indicated by Addenbrooke's Cognitive Examination (ACE) III scores between 75 to 88 (both values included).
  • Self-reported mild difficulties in focus, attention, or memory.
  • Progressive cognitive complaints like stress, disturbed sleep etc. reported by participant.
  • Individuals willing to consume an investigational product from bovine source.
  • Individuals willing to complete all study-related and clinical study visits as per protocol.

Exclusion criteria

  • Clinically diagnosed with Attention Deficit Hyperactivity Disorder (ADHD).
  • Clinically diagnosed with mental disorders (diagnostic and statistical manual of mental disorders: DSM-5-TR), namely but not limited to epilepsy, anxiety, depression or Alzheimer's disease.
  • Individuals with a medical history of cardiac disease, respiratory disorders, kidney disorder, liver disorder, or seizure disorders or other chronic health conditions requiring medication.
  • Individuals with uncontrolled hypertension (systolic blood pressure greater than or equal to 140 mmHg or diastolic blood pressure greater than or equal to 90 mmHg).
  • Individuals with uncontrolled diabetes (fasting blood glucose (FBG) greater than equal to 126 mg/dl).
  • Individuals with history of hypersensitivity to any components of the investigational product.
  • Those taking prescription medication or dietary supplements that affect cognitive function within 30 days prior to screening.
  • Head injury immediately preceding cognitive deterioration.
  • Consumption of excessive amounts of caffeine (more than 4-5 cups per day) and caffeine-containing foods or beverages.
  • Current smokers.
  • Those who are deemed unable to comply with the test requirements or otherwise deemed unsuitable according to the Investigator's opinion.
  • Females who are pregnant/planning to be pregnant/lactating or taking any oral contraceptives.
  • History of drug or alcohol addiction or abuse with the past 12 months.

Treatment and study plan

AP-Brain Collagen Peptide

Dietary Supplement

Single dose once daily

Primary outcomes

  1. Change from Baseline and Different Doses on Selective Attention and Focus by Stroop Color-Word Test at Day 56

    Time frame: Baseline and Day 56

    The Stroop Color Word Test is a validated neuropsychological assessment used to measure selective attention, cognitive flexibility, processing speed, and executive control. The test requires participants to identify the ink color of printed words that may represent incongruent color names, thereby assessing the ability to inhibit automatic responses and manage cognitive interference.

    The change in selective attention and focus will be measured by change in mean reaction time (ms) and stroop latency by Stroop Color-Word test.

Secondary outcomes

  1. Change from Baseline and Different Doses on Selective Attention and Focus by Stroop Color-Word Test at Day 28

    Time frame: Baseline and Day 28

    The Stroop Color Word Test is a validated neuropsychological assessment used to measure selective attention, cognitive flexibility, processing speed, and executive control. The test requires participants to identify the ink color of printed words that may represent incongruent color names, thereby assessing the ability to inhibit automatic responses and manage cognitive interference

    The change in selective attention and focus will be measured by change in mean reaction time (ms) and stroop latency by Stroop Color-Word test.

  2. Change from Baseline and Different Doses on Sustained Attention by Continuous Performance Test (CPT) at Day 28 and Day 56

    Time frame: Baseline, Day 28, and Day 56

    The CPT measures sustained attention of participants to predefined target sequence in two phases (Phase X where participant has to respond to target "X" and phase AX where participant has to respond to target "AX" (e.g., "A" followed by "X") and withhold responses to non-target sequences.

    The change in sustained attention is measured through change in mean response time (ms), omission rates (xtestomissionerrorrate during phase X and axtestomissionerrorrate during phase AX), commission rates (xtestcomissionerrorrate during phase X and axtestcomissionerrorrate during phase AX).

  3. Change from Baseline and Different Doses on Memory by Change in Maximal Digit Span by Digit Span Test at Day 28 and Day 56

    Time frame: Baseline, Day 28, and Day 56

    The Digit Span Test is a standardized neuropsychological measure used to assess working memory capacity and attentional control. It includes two components: Digit Span Forward, in which individuals repeat a sequence of numbers in the same order as presented, and Digit Span Backward, in which they recall the numbers in reverse order.

    The change in memory will be measured by change of maximum digit span the longest correctly recalled sequence length (fML: maximal forward span; bML: maximal backward span) and the mean span, defined as the list length at which 50% of sequences are correctly recalled (fMS: expected forward span correct 50% of the time across 14 trials; bMS: expected backward span correct 50% of the time across 14 trials).

  4. Change from Baseline and Different Doses on Stress by Perceived Stress Scale (PSS) at Day 28 and Day 56

    Time frame: Baseline, Day 28, and Day 56

    The PSS is a 10-item questionnaire with a recall period of 1 month, designed to examine participants' self-reported levels of stress during the past month by examining their thoughts and feelings. Each question is rated on a scale of 0 (never) to 4 (very often). The PSS provides a total score out of 40, where a higher score indicates higher levels of self-perceived stress.

Other outcomes

  1. Brain Function Assessed through Latency and Amplitude by P300 Electroencephalogram (EEG) at Baseline and Day 56

    Time frame: Baseline and Day 56

    Event-related potentials will be elicited using a standard P300 paradigm. P3b latency and P3b amplitude will be quantified.

    P3b latency will be defined as time internal (milliseconds) from stimulus onset to the maximum positive peak within expected P300 time window.

    P3b amplitude will be measured as the voltage difference (microvolts) between baseline and the peak of the P3b component.

  2. Change from Baseline and Different Doses on Synaptic Plasticity by Brain Derived Neutrophic Factor (BDNF) at Day 56

    Time frame: Baseline and 1 hour post-dose Day 56

    Change of BDNF levels to determine acute neurotrophic response and synaptic plasticity via blood sample collection.

  3. Change in Baseline and Different Doses in Stress by Cortisol/Dehydroepiandrosterone sulfate (DHEAS) ratio at Day 56

    Time frame: Baseline and 1 hour post-dose Day 56

    Change in ratio of cortisol/DHEAS levels to determine stress via blood sample collection.

  4. Change in Baseline and Different Doses in Inflammation by Tumor Necrosis Factor Alpha (TNF-α) Levels at Day 56

    Time frame: Baseline and 1 hour post-dose Day 56

    Change of TNF-α levels to determine inflammation via blood sample collection.

  5. Change from Baseline and Different Doses on Oxidative Stress by Malondialdehyde (MDA) Levels at Day 56

    Time frame: Baseline and 1 hour post-dose Day 56

    Change of MDA levels to determine systemic oxidative stress via blood sample collection.

  6. Change in Baseline and Different Doses on Cognition Status by Addenbrooke's Cognitive Examination III (ACE III) at Day 56

    Time frame: Baseline and Day 56

    Change in cognition status will be assessed using the ACE-III. The ACE-III provides a total score out of 100, where a higher score indicates better cognitive function. The assessment covers five cognitive domains of orientation/attention, memory, fluency, language, and visuospatial function.

  7. Change from Baseline and Different Doses on Cyclic Glycine-Proline (cGP) Levels at Day 56

    Time frame: Baseline and 1 hour post-dose Day 56

    Change of cGP levels via blood sample collection.

  8. Change from Baseline and Different Doses on Insulin-Like Growth Factor-1 (IGF-1) Levels at Day 56

    Time frame: Baseline and 1 hour post-dose Day 56

    Change of IGF-1 levels via blood sample collection.

  9. Change from Baseline and Different Doses on Blood Pressure at Day 28 and Day 56

    Time frame: Baseline, Day 28, and Day 56

    Change in vitals assessed through blood pressure with units of mmHg.

  10. Safety Assessed by Liver Function Test from Baseline and Day 56

    Time frame: Baseline and 1 hour post-dose Day 56

    Safety of test product assessed by liver function test obtained via blood sample. The liver function test will include evaluation of aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, alkaline phosphatase, total bilirubin, and total proteins.

  11. Change from Baseline and Different Doses on Pulse Rate at Day 28 and Day 56

    Time frame: Baseline, Day 28, and Day 56

    Change in vitals assessed through pulse rate to provide beats per minute (bpm).

  12. Safety Assessed by Complete Blood Count Monitoring from Baseline and Day 56

    Time frame: Baseline and 1 hour post-dose Day 56

    Safety of test product assessed by complete blood count obtained via blood sample. The complete blood count will include evaluation of hematocrit, hemoglobin, platelet, red blood cell count, white blood cell count, neutrophil, lymphocyte, monocyte, eosinophil, and basophil.

  13. Safety Assessed by Fasting Blood Glucose from Baseline and Day 56

    Time frame: Baseline and 1 hour post-dose Day 56

    Safety of test product assessed by fasting blood glucose levels obtained via blood sample.

Study contacts

Contact information is provided by the study sponsor or research team.

Sanjay Vaze, Dr

CONTACT

[email protected]

+91 8655670964

Sponsors and collaborators

Lead sponsor

Rousselot BVBA

Industry

Collaborators

  • Vedic Lifesciences Pvt. Ltd.

Registry information

Official study title

A Randomized, Open-Label, Parallel Proof-of-Concept Study to Assess the Effect of AP-Brain Collagen Peptides on the Improvement of Attention, Focus, and Memory in Stressed But Otherwise Healthy Individuals

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
May 7, 2026
Registry last updated
Jul 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.